CHEMOPREVENTION FOR PROSTATE CANCER IN PATIENTS WITH BENIGN PROSTATE HYPERPLASIA WITH ELEVATED PROSTATE-SPECIFIC ANTIGEN LEVELS

CHEMOPREVENTION FOR PROSTATE CANCER IN PATIENTS WITH BENIGN PROSTATE HYPERPLASIA WITH ELEVATED PROSTATE-SPECIFIC ANTIGEN LEVELS

Show other versions (1)

The paper gives the comparative results of chemoprevention against prostate cancer (PC) in 189 patients with benign prostate hyperplasia with a prostate-specific antigen (PSA) level of 2.5 to 10.0 ng/ml during 4‑year combined (avodart + omnic) or monotherapy with either drug. Biopsy revealed PC in 1...

Full description

Bibliographic Details
Main Authors: Yu. I. Kushniruk, V. A. Yarosh, M. D. Dyachuk
Format: Article
Language:Russian
Published: ABV-press 2014-07-01
Series:Onkourologiâ
Subjects:
prostate cancer
chemoprevention
benign prostate hyperplasia
combination therapy
monotherapy
avodart
omnic
Online Access:https://oncourology.abvpress.ru/oncur/article/view/139
Description
Summary:The paper gives the comparative results of chemoprevention against prostate cancer (PC) in 189 patients with benign prostate hyperplasia with a prostate-specific antigen (PSA) level of 2.5 to 10.0 ng/ml during 4‑year combined (avodart + omnic) or monotherapy with either drug. Biopsy revealed PC in 14.3 % of the patients treated with avodart and in 29.0 % of those who received omnic monotherapy (p < 0.05). In the avodart groups, the incidence rate of aggressive PC was almost twice the rate in the omnic monotherapy group. The long-term avodart therapy was safe with a stable reduction in the baseline levels of PCA and dihydrotestosterone, and conversely, any PSA rise and even an episodic fall in free PSA ratio are indications for transrectal multifocal prostate biopsy.
ISSN:1726-9776
1996-1812

Similar Items